Celine Halioua, CEO and founder of Loyal, is on a mission to extend the lives of our furry companions with groundbreaking biopharmaceuticals. The discussion dives into her innovative drug, LOY-1, which slows aging in large dog breeds and hints at possible benefits for humans. Celine shares insights on the intriguing link between dog size and lifespan, along with the ethical dynamics of life extension. Plus, she sheds light on the unique challenges her biotech company faces in the pet health market.
A biotech company called Loyl has made progress in developing safe life extension drugs for pets, particularly for large dog breeds.
Developing life extension drugs for dogs involves significant expenses, especially in the realm of clinical trials.
Research into extending the lifespan of dogs is expected to have spillover effects on human longevity.
Deep dives
The Science of Slowing Down the Aging Process with Dogs
A biotech company called Loyl has made progress in developing safe life extension drugs for pets, particularly for large dog breeds. The FDA has acknowledged the reasonable expectation of effectiveness of Loyl's drug Loy1, which works to slow down the aging process in dogs. While the drug is not yet available and not FDA-approved, it has shown promise in reaching the stage of fast-tracked authorization for animal drugs. Loyl's approach is to target specific genetic pathways, such as the growth hormone IGF-1 pathway, which has been linked to longevity. The company aims to extend dogs' lifespan and health span to provide more quality years for pets. The ultimate goal is to develop drugs that can also have spillover benefits for humans in terms of improving age-related health.
The Economic Challenges of Developing Life Extension Drugs for Dogs
Developing life extension drugs for dogs involves significant expenses, especially in the realm of clinical trials. The economics of the pharma industry are different from those of other sectors, with high costs for drug development and regulatory approval processes. Loyal's approach, focusing on cash-to-milestone progress and assuming a high degree of responsibility, follows the externalized R&D model. While some investors may not be familiar with the biotech industry, loyal aims to demonstrate legitimacy by adopting rigorous standards and pursuing FDA-approved drugs. By raising awareness about the economic and scientific aspects of developing life extension drugs for dogs, loyal seeks to build trust and attract investment.
The Potential for Human Longevity Research from Dog Life Extension Studies
Research into extending the lifespan of dogs is expected to have spillover effects on human longevity. Dogs experience age-related diseases similar to humans, making them valuable research subjects. By studying the genetic mechanisms behind aging and age-related diseases in dogs, insights can be gained that may also apply to humans. For example, inhibiting the growth hormone IGF-1 pathway in large dogs has shown potential for extending lifespan. Additionally, understanding metabolic fitness through dietary and genetic interventions has relevance for both dogs and humans. The similarities between the aging processes of dogs and humans make dog life extension studies a valuable avenue for advancing human longevity research.
The Excitement and Skepticism Surrounding Dog Life Extension
The announcement of the potential life extension drugs for dogs has generated significant excitement, particularly among dog owners and veterinarians. The possibility of extending the lifespan and health of beloved pets has been received positively. While there may be ethical and cultural concerns around intervening in the aging process of dogs, the majority of reactions have been enthusiastic. The prospect of improving the quality and longevity of dogs' lives has overshadowed any skepticism. By focusing on the safety and well-being of dogs, along with responsible and rigorous development processes, loyal aims to establish a positive framework for understanding medicine and interventions related to life extension.
Exploring the Economics and Mechanics of Life Extension Pharmaceuticals
The economics of life extension pharmaceuticals differ from traditional business models. The cost structure of the pharma industry revolves around milestone achievements and cash flow. In the case of loyal's life extension drugs for dogs, significant expenses are allocated to research and development, including clinical trials, before generating revenue. Loyal's innovative approach of developing drugs for dogs allows for unique funding strategies, such as expanded conditional approval and direct drug distribution. The goal is to make life extension drugs accessible, safe, and positively perceived within the healthcare landscape, ultimately reshaping how medicine and pharmaceuticals are approached.
Today’s episode is about the science of slowing down the aging process … and why one biotech company has found some success with dogs. Last November, the New York Times reported that a company called Loyal had reached a milestone in the development of safe life extension drugs for our pets. This drug, which is called LOY-1, works to slow the aging process in large breeds. But Loyal's work holds major promise for helping all dogs live longer. It could even crack open some of the mysteries of mammalian aging, which could lead to discoveries that extend the lives of humans.
Today's guest is the CEO and founder of Loyal, Celine Halioua. We talk about her experience as a female biotech founder, the weird economics of pharma, the ethics of life extension, the science of why big dogs die young, her theories for how to slow down the aging process in dogs big and small, and the possibility spillover benefits for humans who would like a few more years with their family and friends.
If you have questions, observations, or ideas for future episodes, email us at PlainEnglish@Spotify.com.
